Israel-based medical device company Keystone Heart has reported positive data from its TriGuard Cerebral Embolic Protection device while it was used during transcatheter aortic valve replacement (TAVR).

TriGuard is a cerebral protection device which has been designed to reduce the amount of embolic material that enters blood circulation to the brain during transcatheter heart valve replacement or implantation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It fully covers all the areas of brain in order to reduce the risk of cerebral damage during TAVR and other cardiovascular procedures.

"Results suggested that the patients treated with TriGuard device did not experience strokes."

The device has been shaped to accommodate varying anatomies of the aortic arch.

It uses a Nitinol frame and mesh which is flexible, atraumatic, it is robust and sturdy and helps in the interface of the device with the TAVR delivery system and other procedure related accessories.

See Also:

The TriGuard Cerebral Protection Device is placed through one of two femoral artery access ports which is generally used in TAVR, hence eliminating the need for a third puncture site.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can be deployed rapidly and adjusts its position through a small 9F catheter which can be removed easily.

The device has been designed to offer stable and atraumatic protection.

Keystone Heart conducted a study involving 51 patients undergoing TAVR to test the safety and efficacy of the TriGuard HDH embolic deflection device to protect brain from lesions during TAVR procedures and compared to the existing standard of care.

Results suggested that the patients treated with TriGuard device did not experience strokes, it also recorded a successful device performance without disrupting the TAVR procedure.

Yale School of Medicine and Yale Cardiovascular Research Group Division of Cardiology Alexandra Lansky said: "These data, together with previously reported positive safety, and clinically meaningful outcomes, reinforce the importance of using TriGuard to protect the brain from damage potentially incurred during TAVR procedures.”